Ranking Profile - Phio Pharmaceuticals Corp
Introduction
Phio Pharmaceuticals Corp (Phio Pharmaceuticals), formerly known as RXi Pharmaceuticals Corp, is a biotechnology company. The company discovers, develops and commercializes immuno-oncology therapeutics based RNAi platform to treat cancer. Its product pipeline includes PH-762, PH-894 and PH-804 for adoptive cell therapy, tumor microenvironment and intratumoral. Phio Pharmaceuticals also provides clinical trial services. Phio Pharmaceuticals offers products for the treatment of anti scarring, macular degeneration, retinoblastoma, and liver diseases. The company partners with academia, biotech, and large multi-national organizations for the development of new therapeutics. Phio Pharmaceuticals is headquartered in Marlborough, Massachusetts, the US.
Company info
Country (HQ): | United States |
Sector: | Pharmaceuticals and Healthcare |
Market Cap (US$ m): | 6 |
Revenue (US$ m): |
Innovation ranking
Innovation score
Closest peers in the Pharmaceuticals and Healthcare sector
Innovation Ranking
Johnson & Johnson
United States
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd
Switzerland
Pharmaceuticals and Healthcare
Phio Pharmaceuticals Corp
United States
Pharmaceuticals and Healthcare
EyeGate Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
Shin Poong Pharm Co Ltd
South Korea
Pharmaceuticals and Healthcare
Are you ranked? Get the Innovation Ranking Report
-
Company Ranking Report
- If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
- Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
- Contextualised information on the company's standing in relation to peers
- Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
- Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
- Rosettes
- Certificate of Achievement
- Press release